26762 Federal Register / Vol. 87, No. 87 / Thursday, May 5, 2022 / Notices 

will also request the information from 

the HHA provider who submitted the 

claim for payment from the Medicare 

program to determine if payment was 

appropriate. Form Number: CMS–10599 

(OMB control number: 0938–1311); 

Frequency: Frequently, until the HHA 

reaches the target affirmation or claim 

approval threshold and then 

occasionally; Affected Public: Private 

Sector (Business or other for-profits and 

Not-for-profits); Number of 

Respondents: 3,631; Number of 

Responses: 1,467,243; Total Annual 

Hours: 7,445,143. (For questions 

regarding this collection contact Jennifer 

McMullen (410)786–7635.) 

Dated: April 29, 2022. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2022–09581 Filed 5–4–22; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity: National Medical Support 

Notice Part A (OMB No.: 0970–0222) 

AGENCY: Office of Child Support 

Enforcement, Administration for 

Children and Families, HHS. 

ACTION: Request for public comment. 

SUMMARY: The Office of Child Support 

Enforcement (OCSE), Administration for 

Children and Families (ACF), is 

requesting a 3-year extension of the 

National Medical Support Notice 

(NMSN) Part A. This request includes 

minor revisions to the NMSN Part A 

form, revisions to and separation of the 

instructions into a stand-alone 

attachment, a Part A sample, and the 

addition of the State Medical Support 

Contacts and Program Requirements 

matrix. The current Office of 

Management and Budget (OMB) 

approval expires on October 31, 2022. 

DATES: Comments due within 60 days of 

publication. In compliance with the 

requirements of the Paperwork 

Reduction Act of 1995, ACF is soliciting 

public comment on the specific aspects 

of the information collection described 

above. 

ADDRESSES: You can obtain copies of the 

proposed collection of information and 

submit comments by emailing 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

SUPPLEMENTARY INFORMATION: 

Description: Federal law requires that 

all child support orders under Title IV– 

D of the Social Security Act include 

medical coverage. The Child Support 

Performance and Incentive Act of 1998 

(CSPIA) requires enforcement of this 

provision; the NMSN Part A is the 

means to enforce health care orders. 

This information collection expedites 

requests for medical coverage between 

state child support enforcement 

agencies and employers. OCSE 

maintains Part A of the NMSN, which 

states initiate and send to a parent’s 

employer to complete. States must 

supply some sensitive information to 

the parent’s employer in order to enroll 

the child(ren) in the correct health 

coverage plan. This information 

includes names, dates of birth, Social 

Security numbers, and addresses. The 

employer retains the income 

withholding part of the form and 

withholds from the employee’s income 

any premium payments the health care 

plan may require. Then, the employer’s 

health care administrator enrolls the 

child(ren) in the health care plan. The 

Department of Labor (DOL) maintains 

Part B of the NMSN. This request 

includes minor revisions to the NMSN 

Part A form, revisions to and separation 

of the instructions into a stand-alone 

attachment, a Part A sample, and the 

addition of the State Medical Support 

Contacts and Program Requirements 

matrix. OCSE will also request from 

OMB that the NMSN Part A expiration 

date match the expiration date of the 

NMSN Part B, which will be submitted 

by DOL. 

Respondents: States and employers. 

ANNUAL BURDEN ESTIMATES

Information collections Respondent 

Total 

number of 

respondents 

Annual 

number of 

responses per 

respondent 

Average 

burden hours 

per response 

Annual 

burden hours 

National Medical Support Notice Part A and 

Instructions.

States ....................................

Employers .............................

54 

1,310,727 

90,194 

3.72 

.17 

.17 

827,981 

828,904 

State Medical Support Contacts and Program Requirements Matrix.States .................................... 54 1 1 54 

Estimated Total Annual Burden 

Hours: 1,656,939. 

Comments: The Department 

specifically requests comments on (a) 

whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Consideration will be given 

to comments and suggestions submitted 

within 60 days of this publication. 

Authority: 45 U.S.C. 303.32; the 

Personal Responsibility and Work 

Opportunity Reconciliation Act of 1996, 

Public Law 104–193; CSPIA, Pub. L. 

105–200, Sec. 401(c); Sec. 609(a)(5)(C) 

of the Employee Retirement Income 

Security Act of 1974. 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–09659 Filed 5–4–22; 8:45 am] 

BILLING CODE 4184–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2022–N–0621] 

Advisory Committee; Anesthetic and 

Analgesic Drug Products Advisory 

Committee; Renewal 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; renewal of Federal 

advisory committee. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 87 / Thursday, May 5, 2022 / Notices 26763 

renewal of the Anesthetic and Analgesic 

Drug Products Advisory Committee by 

the Commissioner of Food and Drugs 

(the Commissioner). The Commissioner 

has determined that it is in the public 

interest to renew the Anesthetic and 

Analgesic Drug Products Advisory 

Committee for an additional 2 years 

beyond the charter expiration date. The 

new charter will be in effect until the 

May 1, 2024, expiration date. 

DATES: Authority for the Anesthetic and 

Analgesic Drug Products Advisory 

Committee will expire on May 1, 2024, 

unless the Commissioner formally 

determines that renewal is in the public 

interest. 

FOR FURTHER INFORMATION CONTACT: 

Moon Hee V. Choi, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–2894, AADPAC@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to 41 CFR 102–3.65 and approval by the 

Department of Health and Human 

Services and by the General Services 

Administration, FDA is announcing the 

renewal of the Anesthetic and Analgesic 

Drug Products Advisory Committee (the 

Committee). The Committee is a 

discretionary Federal advisory 

committee established to provide advice 

to the Commissioner. The Committee 

advises the Commissioner or designee 

in discharging responsibilities as they 

relate to helping to ensure safe and 

effective drugs for human use and, as 

required, any other product for which 

FDA has regulatory responsibility. 

The Committee reviews and evaluates 

available data concerning the safety and 

effectiveness of marketed and 

investigational human drug products 

including analgesics, e.g., abusedeterrent opioids, novel analgesics, and 

issues related to opioid abuse, and those 

for use in anesthesiology and makes 

appropriate recommendations to the 

Commissioner of Food and Drugs. 

The Committee shall consist of a core 

of 11 voting members including the 

Chair. Members and the Chair are 

selected by the Commissioner or 

designee from among authorities 

knowledgeable in the fields of 

anesthesiology, analgesics (such as: 

Abuse deterrent opioids, novel 

analgesics, and issues related to opioid 

abuse), epidemiology or statistics, and 

related specialties. Members will be 

invited to serve for overlapping terms of 

up to 4 years. Non-federal members of 

the committee will serve as Special 

Government Employees, representatives 

or Ex-Officio members. Federal 

members will serve as Regular 

Government Employees or Ex-Officios. 

The core of voting members may 

include one technically qualified 

member, selected by the Commissioner 

or designee, who is identified with 

consumer interests and is recommended 

by either a consortium of consumeroriented organizations or other 

interested persons. In addition to the 

voting members, the Committee may 

include one non-voting representative 

member who is identified with industry 

interests. There may also be an alternate 

industry representative. 

Further information regarding the 

most recent charter and other 

information can be found at https://

www.fda.gov/advisory-committees/ 

anesthetic-and-analgesic-drug-productsadvisory-committee/anesthetic-andanalgesic-drug-products-advisorycommittee-charter or by contacting the 

Designated Federal Officer (see FOR

FURTHER INFORMATION CONTACT). In light 

of the fact that no change has been made 

to the committee name or description of 

duties, no amendment will be made to 

21 CFR 14.100. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app.). For general information 

related to FDA advisory committees, 

please visit us at http://www.fda.gov/ 

AdvisoryCommittees/default.htm. 

Dated: April 29, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–09610 Filed 5–4–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2022–D–0113] 

Clinical Pharmacology Considerations 

for Human Radiolabeled Mass Balance 

Studies; Draft Guidance for Industry; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a draft 

guidance for industry entitled ‘‘Clinical 

Pharmacology Considerations for 

Human Radiolabeled Mass Balance 

Studies.’’ This draft guidance describes 

the FDA’s recommendations regarding 

clinical pharmacology considerations 

for conducting human radiolabeled 

mass balance studies, including 

deciding whether and when to conduct 

the study, designing the study, and 

reporting results. 

DATES: Submit either electronic or 

written comments on the draft guidance 

by August 3, 2022 to ensure that the 

Agency considers your comment on this 

draft guidance before it begins work on 

the final version of the guidance. 

ADDRESSES: You may submit comments 

on any guidance at any time as follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2022–D–0113 for ‘‘Clinical 

Pharmacology Considerations for 

Human Radiolabeled Mass Balance 

Studies.’’ Received comments will be 

placed in the docket and, except for 

those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 


lotter on DSK11XQN23PROD with NOTICES1